GeoVax to Participate at the 35th Annual Roth Conference
March 06, 2023 09:00 ET
|
GeoVax, Inc.
Company Progress to be Discussed During Analyst-Led Fireside Chat ATLANTA, GA, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax to Present at the 2023 BIO CEO & Investor Conference
January 26, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update
November 09, 2022 16:00 ET
|
GeoVax, Inc.
Phase 2 Clinical Trials Advance for COVID-19 and Immuno-Oncology Company Secures Rights to NIH-MVA for Protection Against Monkeypox and Smallpox ATLANTA, GA, Nov. 09, 2022 (GLOBE NEWSWIRE) --...
GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022
October 26, 2022 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and...
GeoVax to Present at Vaccines Summit-2022
October 11, 2022 09:00 ET
|
GeoVax, Inc.
Presentation to Focus on Development of Pan-Coronavirus (Universal) Vaccines to Protect Against Evolving Variants ATLANTA, GA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
GeoVax to Present at Upcoming Investor Conferences
October 06, 2022 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 09:00 ET
|
GeoVax, Inc.
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine (GEO-CM04S1) and Phase 1/2 Clinical Trial for Advanced Head and Neck Cancer (Gedeptin®) ATLANTA, GA, Sept. 07, 2022 (GLOBE...
GeoVax Announces Addition to Its Board of Directors
September 01, 2022 09:00 ET
|
GeoVax, Inc.
Nicole Lemerond, CFA, Brings Healthcare Finance Expertise to the GeoVax Board ATLANTA, GA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization
July 28, 2022 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases...
GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update
July 26, 2022 09:00 ET
|
GeoVax, Inc.
Conference Call to be Held Wednesday, August 3, at 4:30 p.m. Eastern Time ATLANTA, GA, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...